Overview

Study to Evaluate the Response to Treatment and Safety of 0.03% Tacrolimus (FK506) Ointment Administered in Pediatric Patients With Moderate to Severe Atopic Dermatitis

Status:
Completed

Trial end date:
2005-02-01

Target enrollment:

Participant gender:

Summary

Objective of this study is to further assess the response to treatment and safety of 0.03% tacrolimus (FK506) ointment when used for 6 months in pediatric patients with moderate to severe atopic dermatitis, known to be responsive to topical steroids.

Phase:

Phase 3

Details

Lead Sponsor:

Astellas Pharma Inc

Treatments:

Tacrolimus